Luz Ding is The China Project’s Business & Technology staff writer. She is based in Washington, D.C., and covers all things China and U.S.-China related. She previously worked as a researcher for the New York Times in Beijing and a reporter for Caixin Media.
Two military technology suppliers, China Electronics Technology Group (CETC) and SOE Potevio, will merge amid U.S. sanction pressures and Beijing’s push for state-owned enterprises reforms.
After a COVID-fueled online healthcare boom in 2020, JD Health and Ping An Good Doctor both raked in the cash on the Hong Kong Stock Exchange. The Tencent-backed WeDoctor will reportedly follow them in listing its healthcare businesses as soon as next month.
The People’s Bank of China leads the world in digital currency pilots, and now the virtual yuan is going global.
Ant Group and other fintech lenders will need to pay $30 for every $100 it issues under new rules as Chinese regulators tighten requirements for online lending and control on financial risks.
China’s leading early cancer screening biotech firm New Horizon nearly tripled on its IPO day in Hong Kong. The company makes China’s first and only approved early cancer screening test kits.
JD.com, China’s second-biggest ecommerce group after Alibaba, is to launch its third public listing: JD Logistics has filed for a Hong Kong IPO.
TikTok and its Chinese version Douyin are the world’s most lucrative apps aside from games when it comes to in-app payments, and advertising revenue in the U.S. is exploding as the Biden administration declines to enforce previous bans.
Drugs made in China might provide the world’s next cancer treatment breakthroughs, powered by returnee scientists, government incentives, and floods of venture capital.
Despite government attention and the threat of regulation, financial technology remains a white-hot destination for investment among China's tech firms and venture capitalists.